Topiramate: as monotherapy in newly diagnosed epilepsy.

abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

journal_title：CNS drugs

authors： Abudy A,Juven-Wetzler A,Zohar J

更新日期：2011-07-01 00:00:00

abstract：:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the pre...

journal_title：CNS drugs

authors： Stegmayer K,Walther S,van Harten P

更新日期：2018-02-01 00:00:00

abstract：BACKGROUND:Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate. METHODS:All callers who contacted the Israeli Teratology Information Service (TIS) be...

journal_title：CNS drugs

authors： Diav-Citrin O,Shechtman S,Bar-Oz B,Cantrell D,Arnon J,Ornoy A

更新日期：2008-01-01 00:00:00

abstract：:Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...

journal_title：CNS drugs

authors： Pae CU,Tharwani H,Marks DM,Masand PS,Patkar AA

更新日期：2009-12-01 00:00:00

abstract：INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...

journal_title：CNS drugs

authors： Szapary L,Horvath B,Marton Z,Alexy T,Kesmarky G,Habon T,Szots M,Koltai K,Juricskay I,Czopf J,Toth K

更新日期：2004-01-01 00:00:00

abstract：:Frontotemporal lobar degeneration (FTLD) describes a spectrum of clinically, pathologically and genetically heterogeneous neurodegenerative disorders of unknown aetiology. FTLD spectrum disorders collectively represent a leading cause of early-onset dementia, with most cases presenting between 45 and 64 years of age. ...

journal_title：CNS drugs

authors： Seltman RE,Matthews BR

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...

journal_title：CNS drugs

authors： Bordier P,Garrigue S,Lanusse S,Margaine J,Robert F,Gencel L,Lafitte A

更新日期：2006-01-01 00:00:00

abstract：:Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

journal_title：CNS drugs

authors： Brambilla F

更新日期：2001-01-01 00:00:00

abstract：:This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

journal_title：CNS drugs

authors： Jennings MT,Iyengar S

更新日期：2001-01-01 00:00:00

abstract：:The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

journal_title：CNS drugs

authors： Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

更新日期：2007-01-01 00:00:00

abstract：:Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...

journal_title：CNS drugs

authors： Salinas RD,Durgin JS,O'Rourke DM

更新日期：2020-02-01 00:00:00

abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

journal_title：CNS drugs

authors： Papadopoulos D,Mitsikostas DD

更新日期：2019-01-01 00:00:00

abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

journal_title：CNS drugs

authors： Athauda D,Foltynie T

更新日期：2018-08-01 00:00:00

abstract：:Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...

journal_title：CNS drugs

authors： Wagner KJ,Möllenberg O,Rentrop M,Werner C,Kochs EF

更新日期：2005-01-01 00:00:00

abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

journal_title：CNS drugs

authors： Pae CU,Patkar AA

更新日期：2013-05-01 00:00:00

abstract：PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

journal_title：CNS drugs

authors： Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

journal_title：CNS drugs

authors： Tobinick E

更新日期：2011-02-01 00:00:00

abstract：:Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...

journal_title：CNS drugs

authors： McKeage K

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

journal_title：CNS drugs

authors： Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

更新日期：2020-02-01 00:00:00

abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

journal_title：CNS drugs

authors： Connor DF,Steingard RJ

更新日期：2004-01-01 00:00:00

abstract：:Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

journal_title：CNS drugs

authors： Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

更新日期：2016-10-01 00:00:00

abstract：:At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

journal_title：CNS drugs

authors： Arendt G

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...

journal_title：CNS drugs

authors： Lattanzi S,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M,Brigo F

更新日期：2020-11-01 00:00:00

abstract：:Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....

journal_title：CNS drugs

authors： Gonzalez-Latapi P,Bhowmick SS,Saranza G,Fox SH

更新日期：2020-10-01 00:00:00

abstract：:Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

journal_title：CNS drugs

authors： Mackie S,Winkelman JW

更新日期：2015-05-01 00:00:00

abstract：:▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...

journal_title：CNS drugs

authors： Davis R,Markham A

更新日期：1997-08-01 00:00:00

abstract：BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

journal_title：CNS drugs

authors： Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

更新日期：2014-11-01 00:00:00

abstract：:Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

journal_title：CNS drugs

authors： Shelton RC,Osuntokun O,Heinloth AN,Corya SA

更新日期：2010-02-01 00:00:00

abstract：:Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

journal_title：CNS drugs

authors： Syed YY,Keating GM

更新日期：2013-10-01 00:00:00